ArrayExpress Uploader03723PEO4 (ER+) ovarian cancer cellsEstrogen2008 (ER-) ovarian cancer cellsPlacebo2008 (ER-) ovarian cancer cellsEstrogen2008 (ER-) ovarian cancer cellsEstrogenPEO4 (ER+) ovarian cancer cellsEstrogenPEO4 (ER+) ovarian cancer cellsEstrogen2008 (ER-) ovarian cancer cellsPlacebo2008 (ER-) ovarian cancer cellsPlacebo2008 (ER-) ovarian cancer cellsPlacebo2008 (ER-) ovarian cancer cellsEstrogen2008 (ER-) ovarian cancer cellsEstrogenPEO4 (ER+) ovarian cancer cellsPlaceboPEO4 (ER+) ovarian cancer cellsEstrogenPEO4 (ER+) ovarian cancer cellsPlaceboPEO4 (ER+) ovarian cancer cellsPlaceboarrayexpress_sid4Menopausal estrogen (E2) replacement therapy increases the risk of estrogen receptor (ER)-positive epithelial ovarian cancers (EOC)....20959477E-GEOD-22600/profile/8773/arrayexpressuploader215breastbreast cancercancercelldiseaseestrogenhormonelymphlymph nodeDec.12, 2014Falsetissue-specific-pathways-for-estrogen-regulation-oE-GEOD-22600_A-AFFY-44Tissue Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and MetastasisSep.15, 2014Menopausal estrogen (E2) replacement therapy increases the risk of estrogen receptor (ER)-positive epithelial ovarian cancers (EOC). Whether E2 is tumorigenic or promotes expansion of undiagnosed pre-existing disease is unknown. To determine E2 effects on tumor promotion, we developed an intraperitoneal mouse xenograft model using ZsGreen fluorescent ER- 2008 and ER+ PEO4 human EOC cells. Tumor growth was quantified by in vivo fluorescent imaging. In ER+ tumors, E2 significantly increased size, induced progesterone receptors, and promoted lymph node metastasis, confirming that ER are functional and foster aggressiveness. Laser captured human EOC cells from ER- and ER+ xenografted tumors were profiled for expression of E2-regulated genes. Three classes of E-regulated EOC genes were defined, but less than 10% were shared with E-regulated breast cancer genes. Since breast cancer selective ER modulators (SERM) are therapeutically ineffective in EOC, we suggest that our EOC-specific E-regulated genes can assist pharmacologic discovery of ovarian targeted SERM. 15 samples were included in this experiment with a 2x2 factorial design with 2 different cell lines (2008 and PEO4) and 2 different hormone treatments (E for Estrogen and C for Placebo Control) and 4 replicates per treatment. 1 sample was excluded (a replicate of PEO4 with C treatment) because of poor quality.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22600humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22600/samples/